Moderna, Keytruda, Opdivo, AI writing: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Cancer patients may be receiving higher doses and longer courses of expensive drugs than they need. Also, we see Moderna’s stock swing some thanks to profit-taking, and… … I’ve taken to channeling Diogenes these…
